YEAR IN REVIEW
clini cians in deciding which patients to treat with belimumab.
Epratuzamab is a humanized monoclonal anti-CD22 antibody, which modifies the activation of B lymphocytes and produces less B-cell depletion than rituximab. In 2013, Wallace et al. 10 published the results of the EMBLEM study-a phase IIb dose-ranging, randomized, double-blind, placebo-controlled trial of epratuzamab in 227 patients with SLE. Patients with severe renal or cerebral SLE were excluded from this trial. The follow-up period was 12 weeks and the primary outcome measure was responder rate using a novel composite outcome measure which, like the composite measure used in the belimumab trials, 9 incorporated the SLE Disease Activity Index (SLEDAI), the British Isles Lupus Assessment Group index (BILAG) and a Physician Global Assess ment (PGA) of disease activity. This new composite measure, designated BICLA (BILAG-based Combined Lupus Assess ment), defines a responder as some one whose BILAG score has improved, whereas SLEDAI and PGA are no worse and there is no treatment failure. Con versely, definition of response in the belimumab studies required improvement in SLEDAI and no worsening of BILAG or PGA. 9 In the EMBLEM trial, the responder rate in the placebo group was only 21.1%. This rate is con siderably lower than in the LUNAR and belimumab studies, which had placebo res ponse rates of approximately 46% and 44%, respectively. 6, 9 This difference is impor tant because high placebo response could be an important reason for the apparent failure of biologic drugs in clinical trials. The EMBLEM study identified a dose of 2,400 mg per month, given as either 600 mg weekly or 1,200 mg fortnightly, as being most effective: with these dosages, responses were seen by 8 weeks, and at 12 weeks 45.9% of those who received 600 mg epratuzamab weekly and 40.5% of those who received 1,200 mg fortnightly showed a BICLA response (compared with 21.1% of the placebo group). Serious adverse effects were rare and not related to dose of epratuzamab, and no deaths occurred. Though it is important to recognize that EMBLEM was not powered to show a statistically significant benefit of epratuzamab over placebo, this study is an important advance as it identifies a safe, well-tolerated and potentially effective dose of this drug in patients with moderately to severely active SLE. The results of longer, larger phase III trials, which have been initiated, will be crucial.
Thus, 2013 may well be remembered as a time when, after several frustrating years, the potential benefits of biologic therapies in SLE genuinely began to be realized. We hope that 2014 will see more successful trials of biologics in SLE reported, as well as the commencement of other trials using more realistic primary endpoints. T-cell activation. Using two independent SLE cohorts, >485,000 genomic methylation sites were analysed by array. The researchers identified 47 genes as differentially methylated, either hypomethylated or hypermethylated, in a comparison of naive CD4 + T cells from healthy individuals and patients with SLE. Methylation did not increase or decrease with disease activity, as measured by the SLE disease activity index. Bisulphite sequencing confirmed that 35 genes were hypomethy lated, and most of these genes are involved in type I interferon signalling. Many of the hypomethylated genes were known to be overexpressed in total CD4 + T cells from patients with SLE, but methylation state and expression had not previously been studied in the same naive CD4 + T cell. Coit et al. 1 found that none of the hypomethylated genes were overexpressed in naive CD4 + T cells. This discordance between gene accessibility and expression could be explained by the relative paucity and inactive state of transcription factors in naive CD4 + T cells. The changes in DNA methylation before activation and differentiation indicate that naive cells are 'poised' to express those genes even in the absence of other immune signals. This model helps explain the increased expression of IFN-α and type I interferon-inducible genes in patients with SLE. In related work, the same type of genome-wide methylation array was used to analyse B cells, monocytes and CD4 + T cells. 4 Prior to this study, B cells and monocytes from patients with SLE had not been examined in this manner. Absher et al., 4 however, did not study gene expression or confirm changes in DNA methylation by bisulphite sequencing. Similar to the findings by Coit et al., 1 most of the hypomethylated genes were related to the type I interferon signalling pathway. The methylation changes in total CD4 + T cells also did not differ significantly from cell subsets, including naive CD4 + T cells, and they did not vary with disease activity.
The molecular mechanisms by which DNA methylation is regulated in patients with SLE is an area of intense investigation. DNA ( cytosine-5)-methyltransferase 1 (DNMT1) is an ERK-regulated and JNKregulated enzyme required for maintaining methylation patterns in dividing cells. In CD4 + T cells from patients with SLE, the expres sion of DNMT1 is decreased and the ERK and JNK pathways are disrupted. 5 Dis rupting ERK or JNK signalling in vitro decreases Dnmt1 expression and con sequently increases expression of CD70 and other proinflammatory methylation-sensitive genes. 6 Furthermore, disrupting either ERK or JNK signalling in transgenic mice results in an SLE-like dis order characterized by anti-double stranded DNA antibodies and glomerulonephritis. 6, 7 Despite these findings, the mechanisms by which ERK and JNK signalling are disrupted are only partially understood. Work by Sunahori et al. 2 demonstrated that protein phosphatase 2A (PP2A) contributes to disrupted signalling of these pathways in SLE.
Evidence indicates that PP2A is overexpressed in T cells from patients with SLE, compared with T cells from healthy individuals. 8 Protein phosphatases can regulate ERK and JNK signalling, but the specific role of PP2A, if any, in SLE pathogenesis was not previously known. Sunahori et al. 2 developed a model linking the overexpression of PP2A in T cells from patients with SLE with changes in methylation-sensitive proinflammatory gene expression. Blocking PP2A expression in vitro increases ERK and MEK activation and, consequently, DNMT1 expres sion and activity. CD70 and CD11a expres sion, which are regulated by DNA methylation, were also decreased when PP2A was silenced. These findings suggest that PP2A contributes to SLE pathogenesis by blocking ERK and JNK signalling and DNMT1 activity to enable aberrant overexpression of methylation-sensitive proinflammatory genes. This hypothesis would be amenable to testing in an animal model, similar to previous studies in which the ERK and JNK pathways were individually disrupted in transgenic mouse models. 6, 7 DNA methylation and histone modifications regulate gene expression at the level of mRNA transcription, and miRNAs regulate gene expression post-transcriptionally. 9 The role of miRNAs in autoimmune diseases is increasingly recognized, and a major advance was reported in 2013. De la Rica et al. 3 linked DNA methylation, miRNA expression, and mRNA expression in synovial fibroblasts by using a genome-wide methylation array to identify >1,200 genes that are differentially methylated in six patients with osteo arthritis (OA) compared with six patients with RA. An analogous study by Nakano et al. 10 reported similar changes in DNA methylation patterns. De la Rica et al. 3 integrated the methylation data with two different data sets. First, methylation data were compared with mRNA expression data from synovial fibroblasts from patients with RA and OA. With some exceptions, most of the hypomethylated genes had overexpressed mRNAs and many of the hypermethylated genes had underexpressed mRNAs, as would be predicted. Next, miRNA expression in synovial fibroblasts from patients with OA or RA was then compared with the methylation data, in particular the location of hypermethy lated and hypomethylated CpG sites in the genome. 11 miRNAs that are downregulated in patients with RA, compared to patients with OA, were located near hypermethylated CpG sites, and four miRNAs 3 split the results of their complex analysis into groups that suggest the roles of DNA methylation and miRNAs in regulating gene expression. One group consisted of downregulated mRNAs with hypermethylated DNA and increased expression of targeting miRNAs. In this group, DNA methylation and miRNAs work together to suppress gene expression. In a second group of downregulated mRNAs, corresponding DNA elements were hypomethylated, but the number of miRNAs that specifically target that mRNA were increased. In this second group, miRNAs seemed to have a dominant effect on gene expression. In a third group of downregulated mRNAs, corresponding DNA elements were hypermethylated and targeting miRNA levels were decreased. In this group, the dominant effector of gene expression was DNA methylation. Analogous groups of upregulated mRNAs were also found. This is the first report to study the integration of effects of DNA methylation and miRNAs on the pathogenesis of an autoimmune dis order. Despite the small sample sizes involved, many of the results from the methylation screen and mRNA expression profiles overlap with previously reported work. This research highlights the importance of multiple layers of control in regulating gene expression, and it identifies many new potential therapeutic targets. It also supports the role of other, as yet unidentified, molecules in the pathogenesis of RA, possibly explaining the discordant effects that DNA methylation and miRNAs can have on gene expression.
These three reports indicate an important role for miRNA and DNA methylation dysregulation in the pathogenesis of SLE and RA. The maintenance of DNA methylation patterns is sensitive to environmental influences 7 and miRNAs might serve as biomarkers and therapeutic targets. 3 These data suggest new approaches for the diagnosis and treatment of autoimmune diseases.
RHEUMATOID ARTHRITIS IN 2013
Translational medicine in RA -time for change
Pierre Miossec
With every passing year, research on the pathogenesis of rheumatoid arthritis benefits from discoveries in other scientific fields. Three of the best examples that illustrate the benefit of such interdisciplinary bridges and the effects they have on our understanding of rheumatoid arthritis are presented here. 2013 was a prolific year for publication of research related to rheumatoid arthritis (RA) and many criteria could be used to select the three most interesting papers. An obvious aspect to be considered is how the research could change the future-will it lead to a cure? But when do you judge the final effect of a discovery? It takes at least 10 years to move from concept to clinical trials. Research from other fields should also be considered, such as those studies with a global vision of health and disease, and from journals that are not commonly read by rheumatologists. Finally, the major bias for this Year in Review is personal interest and contribution to the field. Combining these aspects, I have selected three studies published in 2013 for their importance to our current understanding of RA pathogenesis.
Given my work on IL-17 and T cells, 1 it is probably no surprise to some that I have selected a paper examining the balance of type 17 helper T (T H 17) cells and regulatory T (T REG ) cells in the context of RA. A key function of T REG cells is to control immune reactions and to suppress the emergence and development of auto immunity. Thus, in chronic inflammatory diseases such as RA, it is not surprising that impaired T REG cell function has been identified, although it is still unclear whether total cell numbers, or just cell functions, are modified. Nie et al. 2 established a functional link between T REG cells, TNF, and the pathogenesis of chronic RA. They found a defect in T REG cell function as a consequence of abnormal phosphorylation of forkhead box protein P3 (FOXP3), the key transcription factor for T REG cell function.
